ESMO 2021: KEYNOTE-355 Update Confirms Benefit of Adding Pembrolizumab to Chemotherapy in Advanced Triple-Negative Breast Cancer
Benefits were greatest among patients with high PD-L1 expression
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.